Outcomes32

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 20 of 32

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants With Progression-free Survival (PFS) as Evaluated by Central Radiologist's Assessment	Month 6	Safety Population	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Project Overall Survival Rate at Month 6	6 Months	Safety Population	Proportion of participants	NUMBER
SECONDARY	Overall Survival (OS)	First dose of study treatment until the date of death due to any cause, whichever came first, a median of approximately 17.67 months	Safety Population	Months	MEDIAN
SECONDARY	Project Overall Survival Rate at Month 12	12 Months	Safety population	Proportion of participants	NUMBER
SECONDARY	Median Progression Free Survival	Month 12	Safety Population	Months	MEDIAN
SECONDARY	Disease Control Rate (DCR), Central Radiologist's Assessment	Month 6	Safety Population	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Disease Control Rate (DCR), Central Radiologist's Assessment	Month 12	Safety Population	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Disease Control Rate (DCR), Central Radiologist's Assessment	End of Study up to 24 months	Safety Population	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Overall (Objective) Response Rate (ORR), Central Radiologist's Assessment	Month 6	Safety Population	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Overall (Objective) Response Rate (ORR), Central Radiologist's Assessment	Month 12	Safety Population	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Overall (Objective) Response Rate, Central Radiologist's Assessment	End of Study as defined up to 24 months	Safety Population	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Summary of Duration of Progression Free Survival, Local Radiologist's Assessment	up to 7 months	Safety Population	Months	MEDIAN
SECONDARY	Progression Free Survival, Local Radiologist's Assessment	Month 12	Safety Population	Months	MEDIAN
SECONDARY	Progression Free Survival, Local Radiologist's Assessment	End of Study as defined up to 24 months	Safety Population	Months	MEDIAN
SECONDARY	Overall (Objective) Response Rate, Local Read	6 Months	Safety Population	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Overall (Objective) Response Rate, Local Reader's Assessment	12 Months	Safety Population	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Overall (Objective) Response Rate (ORR), Local Reader's Assessment	End of Study as defined up to 24 months	Safety Population	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Disease Control Rate (DCR), Local Reviewer	Month 12 as defined by 1 year	Safety Population	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Disease Control Rate (DCR), Local Reviewer	Month 6	Safety Population	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Disease Control Rate End of Study, Local Reviewer	End of Study as defined up to 24 months	Safety Population	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03790111/outcomes

API reference For AI assistants

Outcomes32

Sources 3

Read this list from software.